Outcomes associated with once‐daily versus multiple‐daily dosing of buprenorphine/naloxone for opioid use disorder

Background and Objectives Clinical studies examining once‐daily versus multiple‐daily dosing of buprenorphine/naloxone in patients with opioid use disorder (OUD) in the absence of comorbid pain are lacking. Methods This retrospective chart review aimed to compare 100 patients prescribed single‐daily buprenorphine/naloxone (n = 50) to those prescribed multiple‐daily buprenorphine/naloxone (n = 50) to elucidate the impact that dosing frequency has on negative urine drug screens (UDS) and the number of relapses in OUD. Results The once‐daily cohort produced 84% negative UDSs compared with 74% in the multiple‐daily cohort which was statistically significant (p = .034). There were a total of 43 relapses reported in the once‐daily cohort, compared with 141 relapses in the multiple‐daily cohort (p